Healthitude Life Sciences Pvt Ltd is a global leader in innovative pharmaceuticals and specialty healthcare products, dedicated to enhancing lives worldwide.
Healthitude Life Sciences Pvt Ltd is a global leader in innovative pharmaceuticals and specialty healthcare products, dedicated to enhancing lives worldwide.
CTSTROC-P is a neuroprotective formulation combining Citicoline 500 mg and Piracetam 800 mg, designed to support cognitive function and neurological recovery. It is commonly used in the treatment of stroke, vascular dementia, age-related memory loss, and other neurodegenerative conditions. Citicoline aids in neuronal repair and membrane stabilization, while Piracetam enhances neurotransmission and cerebral blood flow. Available in oral tablet form, CTSTROC-P is typically packaged in blister packs, making it a convenient and effective option in the neurology therapy area.
COMBIMAK-D is a comprehensive neurovitamin formulation containing Methylcobalamin 1500 mcg, Alpha Lipoic Acid 100 mg, Vitamin D3 1000 IU, Pyridoxine HCl 3 mg, and Folic Acid 1.5 mg, specifically designed to manage diabetic and peripheral neuropathies. This combination works synergistically to nourish nerves, reduce oxidative stress, and restore vitamin deficiencies associated with nerve damage. Presented as an oral tablet in blister packaging, COMBIMAK-D is positioned in the neuropathy and nutritional therapy segment, offering effective support for nerve regeneration and overall neuroprotection.
THIATUDE-INJ is a dual-vial injectable formulation composed of Part A (Thiamine 250 mg, Riboflavin 4 mg, Pyridoxine 50 mg) and Part B (Ascorbic Acid 500 mg, Nicotinamide 160 mg, Anhydrous Dextrose 1000 mg), designed to address acute B-vitamin deficiencies, neuropathic conditions, and metabolic stress. This balanced blend of neurotropic vitamins, antioxidants, and energy support agents is used in clinical settings for managing alcoholic neuropathy, post-surgical recovery, and chronic nutritional deficiency states. Supplied in 5 ml ampoules for IM or slow IV injection, THIATUDE-INJ plays a vital role in nerve repair, energy metabolism, and oxidative defense.
CARTITUDE is a comprehensive joint care formulation combining Collagen Peptide Type-II, Glucosamine, Chondroitin, Sodium Hyaluronate, Vitamin C, and Boswellia Serrata Extract, Devils claw Extract and Rosehip Extract designed to support cartilage health, reduce joint inflammation, and improve mobility in patients suffering from osteoarthritis and related degenerative joint disorders. The synergistic action of these ingredients aids in cartilage repair, pain relief, and synovial fluid regeneration, making CARTITUDE an ideal nutraceutical for long-term joint support. Available in oral form and typically packaged in blister strips or bottles, it fits squarely within the orthopedic and joint health therapy segment.
.jpg)
LEVEPTAL (Levetiracetam) is an antiepileptic drug indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. It is available as 250 mg and 500 mg tablets and as 500 mg/5 ml injection. Levetiracetam works by binding to the synaptic vesicle protein SV2A in the brain, which helps modulate neurotransmitter release and reduce abnormal neuronal activity. It can be used as monotherapy or adjunctive therapy in adults and children. Dose adjustment is required in patients with renal impairment. Common adverse effects include drowsiness, dizziness, and irritability, while behavioral changes may occur rarely.
MIGRAWISE is a specialized antimigraine nutraceutical formulation containing Liposomal Magnesium Gluconate, Dibasic Calcium Phosphate, Riboflavin (3.2 mg), and Folic Acid (180 mcg), developed to reduce the frequency and severity of migraine attacks. This unique combination supports neurological stability, vascular tone, and mitochondrial function, which are key factors in migraine prevention. The liposomal form of magnesium ensures higher absorption and bioavailability, making MIGRAWISE a clinically relevant choice in migraine prophylaxis. Conveniently available in oral tablet form, it is typically packaged in blister strips and fits within the neurology and migraine management therapy segment.
.jpg)
UBIMAK is a potent antioxidant and neuroprotective formulation that combines Ubiquinol 100 mg, Vitamin E 100 mg, and Omega-3 Triglycerides 400 mg to support patients with neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s, and other conditions involving mitochondrial dysfunction and oxidative stress. Ubiquinol, the bioactive form of CoQ10, ensures efficient cellular energy production, while Vitamin E and Omega-3s provide synergistic antioxidant and anti-inflammatory benefits. Delivered in an easy-to-take oral softgel or tablet, UBIMAK fits within the neurodegenerative and mitochondrial therapy area, promoting neuronal longevity and cognitive health.
.jpg)
VERTIMAK is a trusted antivertigo therapy containing Betahistine Dihydrochloride in 8 mg, 16 mg, and 24 mg strengths, including a Sustained Release (SR) version for prolonged symptom control. It is indicated in the management of Meniere’s disease, tinnitus, and other vestibular balance disorders. By enhancing inner ear blood flow and facilitating central vestibular compensation, VERTIMAK effectively reduces the frequency and intensity of vertigo episodes. Available in convenient oral tablet form, VERTIMAK is widely used in ENT and neurology practices for long-term management of balance-related symptoms.
CEREMAK is a neuroprotective formulation containing Cerebroprotein Hydrolysate, a mixture of low-molecular-weight neuropeptides that support neuronal survival and repair. It is widely used in the management of acute ischemic stroke, traumatic brain injury, vascular dementia, Alzheimer’s disease, and other neurodegenerative conditions. By promoting neurotrophic activity, enhancing synaptic plasticity, and improving cerebral metabolism, CEREMAK helps restore cognitive and functional recovery in patients with neurological damage. Administered as a lyophilized powder for solution for infusion, CEREMAK is typically supplied in 60 mg vials, offering an effective therapeutic option in neurology for both acute and chronic neuro-rehabilitation.
PALMITEL is a novel, advanced formulation targeting neuropathic pain and neuroinflammation, combining Liposomal Palmitoylethanolamide 300 mg, Lecithin 15 mg, Luteolin 12 mg, and Decarboxylated L-Arginine. This synergistic blend provides endocannabinoid-like modulation, mast cell stabilization, and neuroimmune support, making it effective in managing conditions such as diabetic neuropathy, sciatica, and fibromyalgia. The liposomal delivery system enhances the bioavailability of PEA, while Luteolin adds potent anti-inflammatory benefits. PALMITEL offers a safe, non-opioid approach to chronic pain, fitting well within neurology, pain management, and integrative medicine practices.
PBTUDE-NT is a clinically effective combination of Pregabalin 75 mg and Nortriptyline 10 mg, specially designed for the management of chronic neuropathic pain conditions such as diabetic neuropathy, postherpetic neuralgia, and fibromyalgia. While Pregabalin calms hyperexcitable nerves and reduces pain transmission, Nortriptyline complements by enhancing central pain inhibition pathways. This dual-action formulation provides rapid symptom relief with sustained efficacy, making PBTUDE-NT a go-to choice for neurologists and pain specialists. Available in convenient oral tablet form, it offers a balanced approach to controlling nerve pain with added mood-stabilizing benefits.
.jpg)
RABILTH D is a dual-action gastroprotective formulation combining Rabeprazole 20 mg (Enteric Coated) and Domperidone 30 Mg (Sustained Release), developed for effective management of acid reflux, GERD, and upper GI motility disorders. Rabeprazole offers potent and lasting acid suppression, while Domperidone facilitates gastric emptying and relieves symptoms like bloating, nausea, and epigastric discomfort. The dual-release technology ensures targeted absorption and prolonged symptom control, making RABILTH D a trusted choice among gastroenterologists and general practitioners for comprehensive acid-peptic care.
FLUPITUDE is a fixed-dose combination of Flupentixol 0.5 mg and Melitracen 10 mg, designed for the effective management of anxiety, depression, and stress-related psychosomatic disorders. The synergistic action of Flupentixol’s dopaminergic modulation with Melitracen’s mood-enhancing effect provides rapid relief from emotional instability, low motivation, and mental fatigue. Well-tolerated and fast-acting, FLUPITUDE is ideal for general practitioners, psychiatrists, and gastroenterologists managing functional disorders with an underlying emotional component. Its use is especially valuable in treating patients with anxiety-depression overlap and somatoform symptoms.